AAT (61) CBL (71) UMH (62) ALX (73) ⌘ Pro Terminal →

Medical Properties Trust Inc. (MPT) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell MPT stock right now?

Medical Properties Trust Inc. (MPT) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.

Q: What is MPT's 12-month price target and RQD AI Jury consensus?

MPT's 12-month base price target is $2.26 (range $1.76 to $6.79), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$2.44 -11.27% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Medical Properties Trust Inc. (MPT) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $1.46B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MPT)Realized 20D OHLCV Swing Band: ±12.3%

RSI-14 MOMENTUMOVERSOLD (<32)

19.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE9% OF RANGE

L: $2$2.44H: $6

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on MPT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-6.0% ROIC with 42.0% gross margin and 15.84% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (40)

14/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like MPT

✓Established market leader in Financials with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MPT)

✓Walkthrough of MPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.61%▼ SUPPORT BREAKDOWN

2026-10-30O $2.39H $2.44L $2.06C $2.44VOL 47.93M

RES: $4.37SUP: $2.68SMA50: $3.41SMA200: $4.56

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MPT Butterfly Map → + Track MPT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -2.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MPT)

Financials Rank #963 of 1096 ⚔️ AAT vs MPT Full Matrix →

1. Head-to-Head Financials Peer Comparison (MPT vs. AAT, CBL, UMH, ALX)

Industry: Real Estate Investment Trusts (172 Tracked Issuers)

Across 1096 tracked Financials securities in the Roarable RQD universe, Medical Properties Trust Inc. (MPT) ranks #963 by composite RQD confidence (42/100, grade D-) and #498 by equity capitalization ($1.46B). Within this direct 5-issuer industry benchmark cohort, CBL leads on earnings valuation at 11.6x trailing P/E, while CBL leads on capital efficiency and profitability with 36.3% ROIC and — gross margin. ALX currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with MPT at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MPT ACTIVE Medical Properties Trust Inc.	D-	42/100	—	—	-6.0%	-11.27%	$1.46B	Benchmark Subject
AAT American Assets Trust Inc.	C-	61/100	—	—	11.3%	+3.19%	$1.37B	/aat-vs-mpt →
CBL CBL & Associates Properties Inc.	B-	71/100	11.6x	—	36.3%	+2.28%	$1.57B	/cbl-vs-mpt →
UMH UMH Properties Inc.	C	62/100	—	—	0.7%	+1.54%	$1.30B	/umh-vs-mpt →
ALX Alexander's Inc.	B	73/100	45.1x	—	25.9%	+0.46%	$1.27B	/alx-vs-mpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001287865

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medical Properties Trust Inc. (MPT) reported GAAP revenue of $972.0M (-2.4% vs. FY2024 revenue of $995.5M , and +11.5% cumulative change since FY2023) , GAAP net income of -$277.0M, operating cash flow of $230.8M, and free cash flow of $230.8M (-6.0% YoY). On the balance sheet, MPT closed FY2025 with $15.00B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$972.0M	-$277.0M	$230.8M	$230.8M	$15.00B	—
FY2024 (FY)	2024-12-31	$995.5M	-$2.41B	$245.5M	$245.5M	$14.29B	—
FY2023 (FY)	2023-12-31	$871.8M	-$556.5M	$505.8M	$505.8M	—	—

3. MPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Medical Properties Trust Inc. (NYSE: MPT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $2.44 (-11.27% 1D, market cap $1.46B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1096 tracked Financials issuers, MPT ranks #963 in composite RQD confidence.

How does MPT compare to AAT and CBL in the Financials sector?

Within the Financials sector (Real Estate Investment Trusts), MPT carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.0%. By comparison, AAT (American Assets Trust Inc.) holds a C- grade (61/100 RQD, P/E N/A, ROIC 11.3%, cap $1.37B) and CBL (CBL & Associates Properties Inc.) posts a B- grade (71/100 RQD, P/E 11.6x, ROIC 36.3%, cap $1.57B). Among the 5-stock peer group, CBL leads on earnings multiple (11.6x) while CBL leads on capital efficiency (36.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MPT?

Per MPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001287865), Medical Properties Trust Inc. generated $972.0M in revenue (-2.4% YoY), -$277.0M in net income, and $230.8M in free cash flow against $15.00B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Financials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MPT trading relative to its 50-day, 200-day, and 52-week technical levels?

MPT last traded at $2.44 (-11.27% on volume of 35,765,660 shares), positioning the stock -28.45% below its 50-day simple moving average ($3.41) and -46.49% below its 200-day simple moving average ($4.56). Across its 52-week range of $2.06 to $6.47, MPT sits at the 8.6% percentile with a 14-day RSI of 19.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.3% ($2.14 to $2.74).

MPT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MPT stock right now?

Medical Properties Trust Inc. (MPT) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.

What is MPT's 12-month price target and RQD AI Jury consensus?

MPT's 12-month base price target is $2.26 (range $1.76 to $6.79), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MPT RQD Cockpit MPT 12M Forecast MPT Earnings & Move MPT Dividends & DRIP MPT Insiders & 13F MPT Whale Options MPT Profit Sankey MPT News & Why